Weight Loss Medications and Vision Loss: What Patients Need to Know About a Potential Link to Blindness

Weight-loss drugs have exploded in popularity over the last few years. 

Medications like Ozempic, Wegovy, and Mounjaro have become household names, praised for helping patients lose significant weight and improve other health markers. But as their use has grown, so have reports of serious side effects, including a frightening one: sudden vision loss.

Now, patients across the country are asking the same question: Can weight-loss medication cause blindness?

The answer is not simple, but there is enough evidence and enough concern that people who suffered vision problems after taking these drugs should pay close attention.

Recent studies have raised alarms about a possible association between semaglutide, the active ingredient in Ozempic and Wegovy, and a rare eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION. NAION is a serious optic nerve condition that can cause sudden, painless vision loss, often in one eye, and the damage can be permanent.

For patients who took these medications believing the risks were fully known and properly disclosed, that possibility raises major questions. Were consumers adequately warned? Did drugmakers act quickly enough once reports began to surface? And if a patient loses vision after taking one of these medications, do they have legal options?

What Is NAION? Do Weight-Loss Drugs Cause NAION?

Most of the current concern around weight-loss drugs and blindness focuses on NAION. This condition is sometimes described as a “stroke of the optic nerve.” It typically appears suddenly, without pain, and can cause permanent visual damage. It is already known to occur more often in people with certain vascular risk factors, including diabetes and other circulation-related conditions.

That matters because many patients prescribed GLP-1 drugs already have some of those overlapping risk factors. Drug manufacturers will likely point to that fact. But the legal and medical question is not whether NAION can happen in the general population. The question is whether these medications may increase that risk and whether companies did enough to study, monitor, and warn about it.

Which Weight-Loss Drugs Are Being Linked to Vision Loss? What the Research Has Found So Far

The science is still developing, but it is serious enough that regulators, researchers, and courts are all paying attention.

The strongest current research signal involves semaglutide, the active ingredient in Ozempic and Wegovy. Lawsuits have also named other GLP-1 drugs, but the medical literature and regulatory action highlighted so far have mostly developed around semaglutide.

A 2024 study published in JAMA Ophthalmology found a higher risk of NAION among patients prescribed semaglutide compared with patients prescribed other diabetes or weight-loss medications. In that study, researchers reviewed records from 16,827 patients and reported more NAION events among semaglutide users.

A 2025 multicenter study in JAMA Ophthalmology also found evidence of an association, though it described the increase as smaller than what earlier research suggested. The authors wrote that their findings provided “further evidence of an association” but also emphasized that more research is needed to determine causality and mechanism.

Another 2025 study in JAMA Network Open likewise reported an increased risk signal in certain analyses, while also acknowledging that some prior studies did not find a statistically significant increase. In other words, the research is not perfectly uniform, but it is far from baseless.

Drug companies often defend these cases by arguing that association is not proof of causation. That is true as far as it goes, but product liability cases do not require patients to solve every scientific mystery before asking whether a warning should have been stronger, earlier, or clearer.

Did Regulators Warn About an NAION Risk?

One of the most significant developments came from Europe.

In June 2025, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee concluded that NAION is a “very rare” side effect of semaglutide medicines, including Ozempic, Rybelsus, and Wegovy. The agency said treatment with semaglutide should be stopped if NAION occurs. Internal PRAC materials also stated that product information should be updated to add a warning and list NAION as an adverse effect with a “very rare” frequency.

That does not automatically mean U.S. regulators have reached the same conclusion. But it does undercut any suggestion that the issue is too speculative to take seriously.

As of the current U.S. prescribing information available through FDA label records, Wegovy and Ozempic do not appear to include an NAION warning, and text searches of the current labels do not show “NAION” or “optic” as listed warnings. Mounjaro’s current U.S. label likewise does not appear to include NAION language.

That gap between emerging safety concerns and U.S. label language is exactly the kind of issue that often drives litigation.

Lawsuits Are Already Moving Forward

This is no longer a medical debate. Legal action is happening.

In December 2025, Reuters reported that lawsuits claiming Ozempic, Wegovy, Saxenda, and Trulicity caused blindness or severe vision loss had been centralized in a separate federal multidistrict litigation in Pennsylvania. The litigation focuses on claims that GLP-1 receptor agonist drugs can trigger NAION and that manufacturers failed to adequately warn patients and doctors. Reuters reported that the litigation had grown out of mounting lawsuits filed after the vision-risk studies began drawing attention.

That does not mean every case will succeed, but it does mean courts have recognized that the claims involve common factual and scientific questions serious enough to be handled together.

Why This Matters for Patients

For many people, weight-loss drugs were marketed as life-changing medications, and for some patients, they have been. But patients have the right to weigh benefits against risks, and they can only do that when risks are clearly disclosed.

Vision loss is not a minor side effect. It is life-altering.

A patient who suddenly loses part of their vision may face medical bills, specialist visits, reduced independence, emotional trauma, and lasting damage to their ability to work and drive. If that injury may be tied to a medication they were taking, they deserve honest answers.

They also deserve to know that “rare” does not mean “unimportant.” A side effect can be statistically uncommon and still be devastating when it happens. And when millions of people take a drug, even a very rare complication can affect a substantial number of patients.

What Symptoms Should Patients Watch For?

Patients should take sudden visual changes seriously.

NAION is commonly described as sudden, painless vision loss, usually in one eye. Some people notice blurred or dim vision upon waking. Others experience a shadow or missing area in their visual field. Because optic nerve damage can become permanent, prompt medical attention matters.

Anyone experiencing those symptoms should seek immediate medical care. Patients should not stop or change a prescription medication without speaking to a qualified doctor, but they also should not ignore warning signs involving their vision.

Can I Sue if I Lost Vision After Taking Ozempic or Wegovy?

A potential legal claim will depend on several factors, including:

• When you took the medication.
• Which drug you used.
• Whether you suffered diagnosed vision loss or optic nerve injury.
• Whether your medical records support a connection between the drug and your injury.
• What warnings were provided at the time.

In cases like these, manufacturers often argue that a patient’s underlying health conditions caused the injury instead of the drug. That is why these claims typically require detailed medical review, timing analysis, and expert evaluation.

But if you developed sudden vision loss after taking a GLP-1 weight-loss medication, you may have grounds to investigate whether the manufacturer failed to warn about a known or knowable risk.

How Morgan & Morgan Can Help

When drugmakers put profits ahead of patient safety, the consequences can be permanent.

Morgan & Morgan is investigating claims involving GLP-1 medications and serious vision injuries, including blindness and optic nerve damage. If you or someone you love took a weight-loss medication and later suffered sudden vision loss, our attorneys can review your case and help determine whether you may be entitled to compensation.

Drug injury cases are complex. They often involve dense medical records, evolving scientific evidence, and aggressive corporate defenses. But that is exactly why legal representation matters.

If a medication harmed you, you should not be left to deal with the fallout alone. Hiring a Morgan & Morgan weight-loss drug lawyer is easy, and you can get started in minutes with a free case evaluation.